Christian K. Werner

Christian K. Werner

Auto-generated profile, based on publicly available information

Christian K. Werner

Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 July 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
WZWeihua Zhou
Weihua Zhou
YYYangyang Yao
Yangyang Yao
ASAndrew J. Scott
Andrew J. Scott
KWKari Wilder-Romans
Kari Wilder-Romans
JDJoseph J. Dresser
Joseph J. Dresser
Daniel R. WahlDaniel R. Wahl
Daniel R. Wahl
Intratumoral genomic heterogeneity in glioblastoma (GBM) is a barrier to overcoming therapy resistance. Treatments that are effective independent of genotype are urgently needed. By correlating intracellular metabolite levels with radiation resistance across dozens of genomically-distinct models of GBM, we find that purine metabolites, especially guanylates, strongly correlate with radiation resistance. Inhibiting GTP synthesis radiosensitizes GBM cells and patient-derived neurospheres by impairing DNA repair. Likewise, administration of exogenous purine nucleosides protects sensitive GBM models from radiation by promoting DNA repair. Neither modulating pyrimidine metabolism nor purine salvage has similar effects. An FDA-approved inhibitor of GTP synthesis potentiates the effects of radiation in flank and orthotopic patient-derived xenograft models of GBM. High expression of the rate-limiting enzyme of de novo GTP synthesis is associated with shorter survival in GBM patients. These findings indicate that inhibiting purine synthesis may be a promising strategy to overcome therapy resistance in this genomically heterogeneous disease.

13 August 2020 in Cancer Cell
Verified
Journal Article
Closed access
CCChan Chung
Chan Chung
SSStefan R. Sweha
Stefan R. Sweha
DPDrew Pratt
Drew Pratt
BTBenita Tamrazi
Benita Tamrazi
PPPooja Panwalkar
Pooja Panwalkar
SVSriram Venneti
Sriram Venneti

12 August 2020 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
CWChristian K. Werner
Christian K. Werner
UNUchechi J. Nna
Uchechi J. Nna
HSHanshi Sun
Hanshi Sun
KWKari Wilder-Romans
Kari Wilder-Romans
JDJoseph Dresser
Joseph Dresser
Daniel R. WahlDaniel R. Wahl
Daniel R. Wahl
New approaches are needed to overcome intrinsic therapy resistance in glioblastoma (GBM). Because GBMs exhibit sexual dimorphism and are reported to express steroid hormone receptors, we reasoned that signaling through the androgen receptor (AR) could mediate therapy resistance in GBM, much as it does in AR-positive prostate and breast cancers. We found that nearly half of GBM cell lines, patient-derived xenografts (PDX), and human tumors expressed AR at the transcript and protein level—with expression levels overlapping those of primary prostate cancer. Analysis of gene expression datasets also revealed that AR expression is higher in GBM patient samples than normal brain tissue. Multiple clinical-grade antiandrogens slowed the growth of and radiosensitized AR-positive GBM cell lines and PDXs in vitro and in vivo. Antiandrogens blocked the ability of AR-positive GBM PDXs to engage adaptive transcriptional programs following radiation and slowed the repair of radiation-induced DNA damage. These results suggest that combining blood–brain barrier permeable antiandrogens with radiation may have promise for patients with AR-positive GBMs.

30 October 2023 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
WZWeihua Zhou
Weihua Zhou
ZZZitong Zhao
Zitong Zhao
ALAngelica Lin
Angelica Lin
JYJohn Z. Yang
John Z. Yang
JXJie Xu
Jie Xu
Daniel R. WahlDaniel R. Wahl
Daniel R. Wahl
How cell metabolism regulates DNA repair is incompletely understood. Here, we define a GTP-mediated signaling cascade that links metabolism to DNA repair and has significant therapeutic implications. GTP, but not other nucleotides, regulates the activity of Rac1, a guanine nucleotide-binding protein, which promotes the dephosphorylation of serine 323 on Abl-interactor 1 (Abi-1) by protein phosphatase 5 (PP5). Dephosphorylated Abi-1, a protein previously not known to activate DNA repair, promotes nonhomologous end joining. In patients and mouse models of glioblastoma, Rac1 and dephosphorylated Abi-1 mediate DNA repair and resistance to standard-of-care genotoxic treatments. The GTP–Rac1–PP5–Abi-1 signaling axis is not limited to brain cancer, as GTP supplementation promotes DNA repair and Abi-1-S323 dephosphorylation in nonmalignant cells and protects mouse tissues from genotoxic insult. This unexpected ability of GTP to regulate DNA repair independently of deoxynucleotide pools has important implications for normal physiology and cancer treatment. SIGNIFICANCE: A newly described GTP-dependent signaling axis is an unexpected link between nucleotide metabolism and DNA repair. Disrupting this pathway can overcome cancer resistance to genotoxic therapy while augmenting it can mitigate genotoxic injury of normal tissues. This article is featured in Selected Articles from This Issue, p. 5

12 January 2024
Verified
Other
Open access
PDF file
WZWeihua Zhou
Weihua Zhou
ZZZitong Zhao
Zitong Zhao
ALAngelica Lin
Angelica Lin
JYJohn Z. Yang
John Z. Yang
JXJie Xu
Jie Xu
Daniel R. WahlDaniel R. Wahl
Daniel R. Wahl
Supplementary Data 2 shows Supplementary Methods, Supplementary Reference, Supplementary Figure S1 and Figure Legends, Supplementary Figure S2 and Figure Legends, Supplementary Figure S3 and Figure Legends, Supplementary Figure S4 and Figure Legends, Supplementary Figure S5 and Figure Legends, Supplementary Figure S6 and Figure Legends, and Supplementary Figure S7 and Figure Legends.

12 January 2024
Verified
Other
Open access
WZWeihua Zhou
Weihua Zhou
ZZZitong Zhao
Zitong Zhao
ALAngelica Lin
Angelica Lin
JYJohn Z. Yang
John Z. Yang
JXJie Xu
Jie Xu
Daniel R. WahlDaniel R. Wahl
Daniel R. Wahl
Supplementary Data 1 shows the original data of phosphoproteomic assay in Figure 2.